As of 2026-10-17, the Relative Valuation of TCR2 Therapeutics Inc (TCRR) is (111.12) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.48 USD, the upside of TCR2 Therapeutics Inc based on Relative Valuation is -7608.3%.
The range of the Relative Valuation is (92.22) - (112.16) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.2x - 27.0x | 26.7x |
| Forward P/E multiples | 20.2x - 27.0x | 26.8x |
| Fair Price | (92.22) - (112.16) | (111.12) |
| Upside | -6331.2% - -7678.5% | -7608.3% |
| Date | P/E |